News

Against the buoyant background and trajectory of the PS Biomarker Services business it is now appropriate to expand the executive team with a senior figure strongly connected to the pharmaceutical industry and to split the role of Executive Chairman.

The current year started well with a strong order book, increasing amounts of repeat business and a growing pipeline in biomarker services. With the level of SysQuant^® /TMTcalibrator™ production doubled the increased capacity is being fully utilised at a time when the volume of customer enquiries is rising on a monthly basis and we are looking to further expand the sales team. Current indications point to a strong performance in 2016. 

As global experts in mapping and analysis of protein changes in systems-wide biology, Proteome Sciences plc is strongly encouraged by two recent reports that emphasize the importance of protein profiling to improve outcomes in cancer treatment.

After closing 2015 with a good increase in revenues in the second half, the current year has started well with a strong order book and a growing pipeline in biomarker services.

The Company has received notification from Vulpes Life Sciences Fund (“Vulpes”) that it has a total direct and indirect interest in 36,573,125 ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”) equivalent to 16.04% of Proteome Sciences’ total issued share capital.

From the 8^th Clinical Trials on Alzheimer’s Disease in Barcelona, PS announces that a recently completed study testing its proprietary inhibitors of CK1d reduced the level of tau phosphorylation in a second in vivo model of Alzheimer’s disease tauopathy.